Monoclonal antibodies (mAbs) are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Clonal selection is the process in which antibodies are selected and replicated by the immune system due to them specifically binding to an antigen, such as cancer cells in the case of cancer treatment. This cloning process results in the mass production of antibodies with identical specificity against antigens. This monoclonal property allows for precise targeting of cancer cells and the avoiding of toxicity against healthy cells.

Types of Monoclonal Antibodies Used in Cancer Treatment

There are several different types of monoclonal antibodies that are currently being used in cancer treatment with the goal of enhanced efficacy and reduced side effects:

Naked Monoclonal Antibodies
Unmodified Cancer Monoclonal Antibodies that directly bind to antigens on tumor cells. This binding can result in various anti-tumor effects such as blocking growth receptors or recruiting immune cells to attack the cancer cells. Examples include rituximab for some forms of lymphomas and trastuzumab for breast cancer.

Antibody-Drug Conjugates
Monoclonal antibodies chemically linked to cytotoxic drugs, toxins, or radioactive isotopes. The antibodies act to selectively deliver the attached compound directly to cancer cells while sparing healthy cells. Examples include ado-trastuzumab emtansine for breast cancer and inotuzumab ozogamicin for acute lymphoblastic leukemia.

Bispecific T cell Engager (BiTE) Antibodies
Antibodies engineered with two different antigen binding regions, one side binds to CD3 protein on T cells while the other binds to an antigen on tumor cells. This bridges T cells and cancer cells to induce T cell mediated killing of tumors. Examples include blinatumomab for acute lymphoblastic leukemia and acute myeloid leukemia.

Chimeric Antigen Receptor (CAR) T Cell Therapies
Patients' own immune T cells are genetically modified to produce chimeric antigen receptors (CARs) on their surface, allowing the T cells to specifically recognize a tumor antigen. After infusion, the CAR T cells multiply and attack the cancer. Examples include axicabtagene ciloleucel for lymphomas and tisagenlecleucel for lymphomas and acute lymphoblastic leukemia.

Monoclonal Antibodies in Clinical Trials

While many monoclonal antibodies have gained FDA approval, significant research is still ongoing to expand their applications and improve outcomes. Here are some examples of mAbs currently in clinical trial testing:

- Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate in Phase 3 testing for ovarian cancer. It targets folate receptor alpha that is expressed in over 90% of ovarian tumors.

- Margetuximab (MGAH22) is a Phase 3 trial drug for HER2-positive breast cancer. It targets the HER2 receptor more effectively than trastuzumab.

- Pembrolizumab (Keytruda) is an immune checkpoint inhibitor antibody in combination trials with other drugs for various Advanced solid tumors. It counteracts mechanisms tumor cells use to evade immune response.

- Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody-drug conjugate showing promise in Phase 2 trials for metastatic breast and gastric cancers.

- Sarclisa (isatuximab-irfc) is a CD38-directed monoclonal antibody approved in combination with chemotherapy for relapsed multiple myeloma based on Phase 3 trial results.

Advantages of Monoclonal Antibody Based Therapies

Some major advantages monoclonal antibodies offer as anticancer therapies compared to conventional chemotherapy include:

- Increased specificity against tumor antigens results in greater efficacy against cancer cells with less toxicity against normal cells.

- As targeted therapeutics, they work via multiple mechanisms such as blocking growth factor signaling, induction of apoptosis in cancer cells, initiating immune response against tumors.

- Monoclonal antibodies have been engineered with even higher specificity by linking them to toxins, radioactive isotopes, or immune cells like CAR T cells to further enhance anti-tumor potency.

- With advances in antibody engineering and drug conjugation techniques, their therapeutic windows and areas of application are continually expanding based on ongoing clinical research.

- They represent a relatively new and rapidly advancing form of personalized medicine allowing treatment tailored to a patient's specific tumor characteristics and biomarkers.

In the monoclonal antibodies have emerged as an innovative pillar of cancer immunotherapy. Continued development of newer antibody constructs and combination regimens hold promise to substantially improve outcomes for many cancer types. Ongoing clinical trials seek to optimize their safety profile while maximizing therapeutic benefits for patients.

Get This Report in Japanese Language: 癌モノクローナル抗体

Get This Report in Korean Language: 암 단일 클론 항체

About Author:

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)